Mirus Bio receives ISO 13485:2016 certification, underscoring the quality of processes used to support GMP product portfolio. Read more

mirus bio logo
Search
Close this search box.
Introducing RevIT™
AAV Enhancer
Designed to deliver a higher AAV titer for any serotype, transfection reagent, HEK 293 cell line, or media
Learn More
Nucleic Acid Delivery
Powered by
Intentional Design
For ground-breaking discoveries and advanced therapies
Get started

Transfection Solutions from Bench to Bioreactor

Whether you’re producing viral vectors at clinical and commercial scales, manufacturing recombinant proteins and monoclonal antibodies, performing knock-out studies with siRNA, or editing genes using CRISPR, we have the nucleic acid delivery system you need.

Transforming the Science of Transfection since 1995

Mirus was founded in 1995 to address the limitations and risks of viral gene transfer. We developed the first pDNA transfection method that combined high efficiency with low cellular toxicity, and since that time, we’ve focused on applying intentional design to nucleic acid delivery systems.

 
Homepage collage

Proven Transfection for Therapeutic Viral Vector Manufacturing

TransIT-VirusGEN® Transfection Reagent is designed to enhance delivery of packaging and transfer plasmids to adherent and suspension HEK 293 cell types to increase recombinant adeno-associated virus (AAV) and lentivirus production.

Overcoming Challenges with Viral Vector Optimization

In this podcast, listen to the first-hand account of how researchers from St. Jude overcame the challenges with viral vector optimization to produce ground-breaking gene therapy for hemophilia with the hope to start treating patients on a large-scale in 2023.